The development of monoclonal antibodies (mAbs) has provided vast opportunities to treat a wide range of diseases from cancer to viral infections. While plant-based production of mAbs has effectively lowered the upstream cost of mAb production compared to mammalian cell cultures, further optimization of downstream processing, especially in extending the longevity of Protein A resin by an effective bulk separation step, will further reduce the overall prohibitive cost of mAb production. In this study, we explored the feasibility of using aqueous two-phase separation (ATPS) in capturing and separating plant-made mAbs from host proteins. Our results demonstrated that an anti-West Nile virus mAb (E16) was efficiently separated from most plant host proteins by a single ATPS step, comprising the mixing of plant extracts containing Hydrophobin-Protein A fusion protein (HPA) and E16 and the subsequent incubation with an inexpensive detergent. This simple ATPS step yielded a highly enriched E16 mAb preparation with a recovery rate comparable to that of Protein A chromatography. The ATPS-enriched E16 retained its structural integrity and was fully functional in binding its target antigen. Notably, HPA-based ATPS was also effective in enriching E16 from plant host proteins when both HPA and E16 were produced in the same leaves, supporting the potential of further streamlining the downstream purification process. Thus, ATPS based on plant-produced HPA in unpurified extract is a cost-effective yet efficient initial capture step for purifying plant-made mAbs, which may significantly impact the approach of mAb purification.
Introduction
Monoclonal antibodies (mAbs) have dramatically transformed how we approach the treatment of a myriad of diseases [1] . Examples of mAb-therapeutics include cetuximab to treat colorectal cancer [2] , avelumab to treat a variety of tumors [3] , and the combination of three anti-Ebola mAbs, known as ZMapp, to treat Ebola virus infection [4] . However, the high production cost of mAbs using mammalian cell-based platforms translates into a high market price for approved treatments. Plant-made mAbs have shown great potential in reducing the upstream costs of producing these valuable biologics by eliminating the need for expensive facilities, bioreactors, and culture media required for mammalian cell-based protein production [5] . Although the upstream processing costs can be addressed through plant-based expression platforms [6] , the downstream processing remains essentially equivalent to the 
Purification of mAb from Plant Extract via ATPS
We evaluated the effectiveness of ATPS in purifying plant-made mAb with plant extracts from leaves harvested at 7 DPI. This sampling point was chosen because the levels of expression were high for both HPA (155.2 μg/g FLW) and E16 (339.9 μg/g FLW). A clarified extract from HPA and E16expressing leaves was mixed volumetrically 1:1 and processed through the ATPS steps. As a reference, an aliquot of the same E16 extract was processed in parallel in Protein A affinity chromatography. As shown in Figure 2 , ATPS significantly enriched E16, with HC and LC being the prominent protein bands on the SDS-PAGE. Compared to Protein A chromatography-purified samples, a few more minor non-mAb bands were observed in the lane containing the ATPS-enriched E16 sample (Figure 2 , Lane 3 compared to Lane 6). Specifically, densitometry analysis showed that the purity of ATPS-enriched E16 is ~24% less than that of E16 purified by a two-step process of low pH precipitation and Protein A chromatography [22] . Nevertheless, this single ATPS step did remove most of the plant host proteins from the E16 purification feedstream. The recovery rate of E16 through ATPS was 47.7% ± 5.2%, as measured by ELISA, comparable to that of Protein A chromatography [22] but higher than that reported for ATPS purification of mAbs from hybridoma supernatants (24%) [20] . According to our expression data, the molar ratio of HPA:mAb used in ATPS to achieve this recovery rate was approximately 2:1 (1:2 mass ratio). Thus, this favorable ratio [20] may have contributed to the high recovery of E16. Compared with Protein A chromatography, ATPS is simpler and is less expensive. For example, the crude clarified leaf extract in Lane 2 ( Figure 2 ) can be directly used in ATPS for E16 purification. In contrast, the crude extract had to go through a bulk separation step (overnight low-pH precipitation) to remove host proteins (i.e., Rubisco) and other contaminants to yield the starting extract for Protein A chromatography (Figure 2, Lane 4) . This bulk separation step is necessary as the removal of most abundant plant host protein (Rubisco) (evidenced by the reduction of the ~ 50 kDa band intensity from Lane 1 to Lane 4) and other impurities are essential to 
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Characterization of ATPS-Purified E16 mAb
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Antigen Specificity of ATPS-Purified E16
E16 recognizes a conformational epitope consisting of four discontinuous polypeptides on the surface of the domain III (DIII) of the WNV E protein [25] . Therefore, the binding between E16 and DIII is highly specific and contingent upon the structural integrity of both proteins. To verify that ATPS-enriched E16 retains recognition for its epitope, a binding assay utilizing a yeast display system was performed [22] . Flow cytometric analysis revealed that the incubation of ATPS-purified E16 with WNV DIII-displaying yeast cells resulted in an E16-specific peak that shared a similar percentage of positive yeast cells and fluorescent intensity with that of the Protein A column-purified E16 (Figure 4 ). This provides additional evidence that ATPS enrichment does not alter the mAb's specificity to its antigen, further supporting the use of this method for purifying mAbs that require functional integrity. 
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E16 recognizes a conformational epitope consisting of four discontinuous polypeptides on the surface of the domain III (DIII) of the WNV E protein [25] . Therefore, the binding between E16 and DIII is highly specific and contingent upon the structural integrity of both proteins. To verify that ATPS-enriched E16 retains recognition for its epitope, a binding assay utilizing a yeast display system was performed [22] . Flow cytometric analysis revealed that the incubation of ATPS-purified E16 with WNV DIII-displaying yeast cells resulted in an E16-specific peak that shared a similar percentage of positive yeast cells and fluorescent intensity with that of the Protein A column-purified E16 ( Figure  4 ). This provides additional evidence that ATPS enrichment does not alter the mAb's specificity to its antigen, further supporting the use of this method for purifying mAbs that require functional integrity. Yeast cells displaying domain III of WNV E protein were incubated with ATPS-enriched E16, Protein A column-purified E16 (positive control), or a generic human IgG (hIgG, negative control), and then stained with a Fluorescein isothiocyanate (FITC)-conjugated antibody. Yeast cells were then processed by flow cytometry to monitor the specific binding of E16 to WNV E domain III (DIII).
ATPS with Co-expression of E16 and HPA in Plants
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Materials and Methods

Materials
The salts for phosphate buffered saline, sodium L-ascorbate, carbonate, bicarbonate, citric acid, yeast nitrogen base without amino acids, yeast synthetic drop-out medium supplements, ammonium persulfate, tetramethylethlyenediamine (TEMED), glucose and galactose were all purchased from Sigma-Aldrich (St. Louis, MO, USA). Coomassie Brilliant Blue R-250 and OmniPur®phenylmethylsulfonyl fluoride (PMSF) were purchased from EMD Chemicals (Gibbstown, NJ, USA). Ethylenediaminetetraacetic acid (EDTA), Tween-20, Tris-base and sodium dodecyl sulfate (SDS) were purchased from Fisher Scientific (Fair Lawn, NJ, USA). All detection antibodies used for ELISAs and Western blots were purchased from SouthernBiotech (Homewood, AL, USA). Plates used for ELISAs were purchased from Corning (Kennebunk, ME, USA). The KPL 3, 3 , 5, 5 -tetramethylbenzidine (TMB) peroxidase substrate kit for ELISA was purchased from SeraCare (Milford, MA, USA). Proteomics grade Triton X-114 was purchased from Amresco®Chemicals (Solon, OH, USA). Electrophoresis grade glycine was purchased from MP Biomedicals LLC (Solon, OH, USA). 2-methylpropan-1-ol (isobutanol) was purchased from Acros Organics (Fair Lawn, NJ, USA). Centrifugal filter units were purchased from Millipore (Billerica, MA, USA). Pierce detergent removal spin columns, Millipore Express PLUS 0.22µm vacuum membranes and Pierce ECL Western blotting substrate were all purchased from Thermo Scientific (Rockford, IL, USA). MabSelect resin was purchased from GE Healthcare (Upsala, Sweden). 30% (29:1) acrylamide/bis solution and polyvinylidene fluoride (PVDF) membrane were purchased from Bio-Rad (Hercules, CA, USA).
Bacterial Strains and Growth
The coding sequence of HPA [20] was cloned into the MagnIcon vector pICH11599 and transformed into Agrobacterium tumefaciens GV3101 cells as described previously [35] .
Agroinfiltration
N. benthamiana plants were grown and infiltrated with target gene-harboring A. tumefaciens GV3101 strains as previously described [36] . Specifically, A. tumefaciens strains containing the E16 HC 3 module, E16 LC 3 module [22] , their corresponding 5 modules, and the integrase construct [37] in the MagnICON system were co-infiltrated into leaves of 5-7-week old N. benthamiana with a combined OD 600 of 0.74. GV3101 strains containing the HPA 3 module, the 5 module, and the integrase module were co-infiltrated into leaves with a final OD 600 = 0.9.
For co-expression of E16 and HPA in the same leaves, the six strains of GV3101 required for E16 HC, LC and HPA expression were co-infiltrated into the leaves N. benthamiana plants with a final OD 600 of 0.98 as described previously [38] .
HPA ELISA
HPA-expressing leaves were homogenized in 1× PBS (8 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 , 15 mM NaCl, 2.5 mM KCl) pH 7.4, supplemented with 10 mg/mL of sodium L-ascorbate, 2 mM PMSF, and 1mM EDTA in a fresh leaf mass to buffer volume ratio of 1:1.5 [39] . The plant extract was then clarified by centrifugation twice at 16,873× g for 10 min at 4 • C. Samples were then diluted in 100 mM bicarbonate buffer (pH 9.2) along with the HPA standard, ranging from 50 ng/mL to 0.78 ng/mL in a 96-well plate. The plate was then incubated at 37 • C for 2 h. After blocking with 5% skim milk in PBST (1× PBS with 0.05% Tween-20), generic human IgG was added to the plate to interact with the antibody-binding domain of HPA coated on the plate. The plate was incubated at 37 • C for 1 h, and a horseradish peroxidase-conjugated goat anti-human kappa chain was added as the detection antibody. The plate was developed with TMB and then read at 450nm as previously described [40] . Protein expression level was then calculated as micrograms of recombinant protein per gram of fresh leaf weight (FLW).
Aqueous Two-Phase Separation
Leaves expressing each recombinant protein (HPA or E16) were harvested at 7 days post infiltration (DPI) and homogenized in extraction buffer separately in a blender as described [41] . After clarification by centrifugation, equal volumes of E16 and HPA infiltrated leaf extract were mixed and incubated at 4 • C for 1 h. The mixed extract was then diluted 1:10 in PBS pH 7.4 and incubated in a 26 • C water bath for 5 min. Triton X-114 was added to 1mL of the pre-warmed mixed extract at a concentration of 4% w/v and mixed well. Phase separation was achieved by a 5-min incubation in at 26 • C. The upper aqueous phase was removed and 0.5 mL of 100 mM glycine-HCl (pH 2.0) was added to the lower detergent-rich phase and thoroughly mixed to dissociate E16 from HPA. After phase separation as described above, the upper phase containing the enriched E16 was transferred to another tube and pH adjusted to pH 7.0 with 1M Tris-base. The HPA fusion protein was recovered by adding isobutanol to the lower detergent-rich phase as described previously [20] . The same ATPS procedure was followed when HPA and E16 were co-expressed in the same leaf, except there was no separate homogenization and mixing of leaf extracts. When necessary, the enriched E16 fractions were concentrated with a 100K MWCO centrifugal filter unit and passed through a detergent removal spin column before further analysis.
Protein A Affinity Chromatography of E16
For use as a reference standard, plant-expressed E16 was also purified by Protein A affinity chromatography as described previously [42] . Briefly, control leaves infiltrated with the E16 construct were homogenized as described above, with the exception that the extraction buffer pH was 5.2. After clarification by centrifugation, the plant extract was re-adjusted to pH 5.2 and further incubated overnight at 4 • C. After removal of the precipitated plant host proteins by centrifugation, the extract was adjusted to pH 7.2, filtered through a Millipore Express PLUS 0.22µm membrane. The filtered extract was then loaded onto a Protein A column with MabSelect resin at a rate of 0.8-1.2mL/minute. E16 was eluted from the Protein A column with 100mM citric acid, which was then neutralized with 1M Tris-base.
SDS-PAGE and Western Blotting
Fractions of the starting extract and the flow through (Protein A column) or upper phase (ATPS), along with equivalent amounts of purified E16 from both methods were subjected to reducing SDS-PAGE on a 12% gel and stained with Coomassie Brilliant Blue R-250. For co-expression, only the ATPS samples were included. The purity of E16 mAb was determined by imaging and quantitating Coomassie blue-stained protein bands on SDSPAGE using a densitometer as described previously [43] . For Western blot analysis, ATPS and column-purified E16 samples were separated via SDS-PAGE on 12% or 4-20% gradient gels under reducing or non-reducing conditions, respectively, and then transferred to a PVDF membrane. After blocking with 5% milk in PBST, the membranes were probed with either goat anti-human gamma chain-HRP or kappa chain-HRP antibody diluted in 1% milk in PBST. After washing with PBST, Pierce ECL Western blotting substrate was mixed according to the manufacturer's instructions and used to cover the membrane. The ImageQuant LAS 4000 imager and associated software was then used to image the blots.
E16 ELISA for ATPS E16 Recovery
Recovery of E16 purified from ATPS was quantified by an ELISA as previously described [42] . Briefly, 96-well plates were coated with the WNV domain III (DIII) of the E protein [41] . After blocking with 5% milk in PBST, fractions from the various ATPS purification steps were added to the wells, along with mammalian cell-produced E16 as a standard [37] . A goat anti-human kappa chain-HRP was used as the detection antibody. The plate was then developed with TMB and read with a plate reader at 450nm. E16 recovery by ATPS was calculated as the percentage of purified E16 obtained from the total E16 in the mixed plant extract.
Yeast Display Assay
The yeast display assay was adapted from our published procedure [22] . Saccharomyces cerevisiae EBY100 cells harboring the gene for WNV DIII in the yeast surface display vector, pYD1, were grown in synthetic yeast medium with 2% glucose at 30 • C until log phase growth was reached (OD 600 2-5). Cells were then grown an additional 36 h at room temperature in synthetic yeast medium with 2% galactose to induce expression and display of DIII on the yeast surface. Cells were collected, washed, and incubated with ATPS-enriched E16, Protein-A-purified E16 (positive control) or a generic human IgG (negative control). Cells were then stained with goat anti-human IgG-FITC and counted with a Gallios flow cytometer.
Conclusions
The use of plants as a production platform for mAb therapeutics has great potential to not only reduce the upstream cost of production [6] , but also provide opportunities to improve efficacy and safety [40, 44, 45] . However, the downstream processing costs between plant and cell culture-based platforms remain essentially equivalent, highlighting the need for alternatives or improvements to the current methods for mAb purification [46] . Removing as many contaminating molecules as possible by introducing an efficient yet inexpensive initial capture step, as described here, will prolong the longevity of the Protein A resins in the affinity chromatography step that are the current gold standard for mAb purification. In this study, we built upon the novel concept of utilizing a bifunctional fusion protein to capture a mAb in an ATPS to reduce downstream costs of purifying mAbs from plants. By expressing both the E16 mAb and the HPA fusion protein in plants, directly mixing plant extracts in a controlled ratio, and enriching the mAb through the facile ATPS method described here, we were able to produce a highly enriched E16 mAb with a recovery rate comparable to that obtained from the conventional Protein A affinity chromatography. Furthermore, the recovered mAb was fully assembled and fully functional by retaining recognition of its target antigen. This highly enriched E16 preparation not only can be easily purified to homogeneity by the Protein A affinity chromatography step but may also increase the longevity of the Protein A resin due to the reduction of host proteins in the feedstream of the affinity chromatography. Of note is the demonstration of a mAb and the HPA fusion protein being co-expressed within the same plant and the subsequent enrichment of the mAb via ATPS with an inexpensive detergent. These steps towards improving the purification methods of plant-made mAbs are promising and warrant further optimization and studies on a larger scale to validate the utility of this system.
